Keyword: Evelo Biosciences
The Flagship Ventures-backed microbiome startup has the strong support of its existing investors, who will contribute $40 million to the IPO.
The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.
Evelo Biosciences has just forged closer ties with a heavyweight academic partner for its monoclonal microbials R&D, which envisages using bacteria to fight disease.
Evelo Biosciences has raised $50 million to take its monoclonal microbials into the clinic.